Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 -- Reneo...
United States Gregoryj Flesher Danielle Spangler Ematthew Purcell Russo Partners Reneo Pharmaceuticals Inc
Source: marketscreener.com